Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
N/A
1(33.3%)
3Total
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01039285Phase 4Completed

Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia

Role: lead

NCT00389909Phase 4Completed

Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants

Role: lead

NCT02054507Not ApplicableCompleted

Prematurity Related Risks of Cognitive Impairment at School Age

Role: lead

NCT00817921Completed

Effect of Prematurity on Renal Function in 5 Years Old Children

Role: lead

All 4 trials loaded